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ORIGINAL ARTICLE
A five-factor biomarker profile obtained week 4–12 of treatment for improved
prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2
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ABSTRACT
Background: Several biomarkers of treatment efficacy have been associated with a better prognosis
in patients with metastatic renal cell carcinoma (mRCC). The prognostic significance of biomarkers
in the early treatment phase is unclear.
Material and methods: In a complete national cohort of mRCC patients receiving first-line tyrosine
kinase inhibitors (TKI) or interleukin-2 based immunotherapy (IT) from 2006 to 2010, overall survival
(OS) was analysed for baseline International mRCC Database Consortium (IMDC) classification
factors and on-treatment time-dependent biomarkers obtained day 1 each cycle week 4–12 after
treatment initiation with multivariate analysis and bootstrap validation.
Results: A total of 735 patients received first-line TKI (59%) or IT (41%). Median OS was overall
14.0 months and 33.4, 18.5, and 5.8 months for baseline IMDC favourable, intermediate, and poor
risk groups, respectively (p50.0001). Systolic blood pressure140 mmHg, neutrophils5lower level
of normal (LLN), platelets5LLN, sodium LLN, and LDH1.5 times upper level of normal after
treatment initiation were significantly associated with favourable OS independent of baseline IMDC
risk group in multivariate analyses stratified for TKI and IT (p 0.04). Concordance (C)-index for
IMDC classification alone was 0.625 (95% CI 0.59–0.66) and combined with the five-factor biomarker
profile 0.683 (95% CI 0.64–0.72). For patients with good (3–5 factors) and poor (0–2 factors)
biomarker profile median OS were 23.5 and 9.6 months, respectively (p50.0001). Adding the five-
factor biomarker profile significantly improved prognostication in IMDC intermediate (25.7 vs. 12.0
months, p50.0001) and poor (12.8 vs. 6.4 months, p50.0001) risk groups. A trend was seen in
IMDC favourable risk group (38.9 vs. 28.7 months, p¼ 0.112).
Conclusion: On-treatment hypertension, neutropenia, thrombocytopenia, LDH below 1.5 times
upper level of normal, and normal sodium, obtained week 4–12 of treatment, are independent
biomarkers of favourable outcome in mRCC, independent of treatment type.
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The introduction of tyrosine kinase inhibitors (TKI) has resulted
in a major change in the treatment of patients with metastatic
renal cell carcinoma (mRCC). Overall survival (OS) has been
improved and a higher number of patients are now able to
receive treatment compared with the cytokine era [1].
However, mRCC is a heterogeneous disease where patients
vary with regard to their disease course and many real-life
patients still have a poor outcome. An early identification of
patients with a higher probability to benefit from treatment
would aid the clinical decision whether to keep these patients
on treatment or consider alternative treatment options.
Biomarkers to improve prognostication or to predict respon-
siveness to a particular treatment are therefore highly needed.
For patients treated with TKI, the development of hyper-
tension [2–4], hypothyroidism [5], or thrombocytopenia [4]
during treatment have independently been associated with
improved OS. The development of neutropenia [4] during
treatment or normal baseline sodium [6–8] have independently
been associated with favourable outcome both for patients
treated with TKI or immunotherapy. However, adding these
biomarkers to established prognostic models [9–13] have not
been attempted and the clinical implication of the biomarkers
restricted to the early treatment phase is unknown.
The aim of this study was to assess paraclinical data
obtained week 4–12 after treatment initiation in a com-
plete national cohort of mRCC patients and to integrate
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 2015 Taylor & Francis
independent biomarkers in an established prognostic model in
order to improve prognostication.
Patients and methods
This population-based analysis comprised a complete national
cohort of Danish patients who received TKI (sorafenib and
sunitinib) or interleukin-2 (IL2)-based immunotherapy (sub-
cutaneous low-dose IL2 mainly administered as a two-week
on/two-week off schedule and interferon-alpha given four
weeks on) as first-line treatment from 1 January 2006 to 31
December 2010. The clinical results have previously been
published [1]. A central pathology review confirmed mRCC.
Baseline patient characteristics, outcome data, and paraclinical
data were collected retrospectively with uniform data collec-
tion templates. Blood pressure (BP) and blood samples (BS)
were measured on day 1 in each cycle for the first 12-week on
treatment (week 4–12). BS were standardised to upper (ULN)
and lower level of normal (LLN) for the treating hospital. If
neutrophils or platelets were measured below LLN, haemoglo-
bin or sodium at or above LLN, calcium at or below ULN, LDH
at or below 1.5ULN, and thyroid-stimulating hormone (TSH)
above ULN at any time after baseline but within or equal to
12 week (week 4–12) after treatment initiation the patient
would remain in the category despite subsequent reversal of
values. Hypertension was defined as systolic BP (SBP) above or
equal to 140 mmHg or diastolic BP (DBP) above or equal to
90 mmHg.
Statistical analysis
OS was defined from start of first-line treatment to death of any
cause. Patients alive were censored at time of last follow-up.
Data were right-censored. Patients who emigrated (n¼ 4) were
censored at time of last contact. OS was calculated with
Kaplan-Meier method and median follow-up with the reverse
Kaplan-Meier method. All analyses were complete cases.
BS and BP within 12 weeks (week 4–12) after treatment
initiation were analysed as binary time-dependent covariates
along with baseline IMDC risk groups in a univariate Cox
proportional hazard model. A multivariable time-dependent
Cox regression analysis with time-dependent covariates and
baseline IMDC risk groups including covariates with a
univariate p 0.1 was performed. The model was then reduced
retaining covariates with two-sided p50.05. The model was
stratified for TKI and IL2-based therapies after prior test for
interaction between drug and time-dependent covariates and
analysed separately for TKI and IL2-based therapy.
A prognostic index was constructed based on all significant
time-dependent covariates from the stratified multivariate
model. A forest plot was created to demonstrate the effect of
adding covariates to the index by assigning all significant time-
dependent variables 1 point each except LDH and then scored
by the sum. The multivariate model was validated internally with
bootstrap analysis with 300 random samples. Concordance (C)-
index was used to evaluate both the original and the bootstrap
models predictive accuracy where a value of 0.5 represents no
predictive accuracy and 1 represents complete accuracy that is
patients predicted to survive will actually survive [14].
Database management and statistical calculations were
performed using SAS (v9.3, SAS Institute, Cary, NC, USA) and R
[R Core Team (2013)].
Ethics
The study was approved by the Danish Health Authorities,
the Danish Research Ethics Committee and the Danish
Data Protection Agency. The study was registered with
ClinicalTrials.gov NCT01339962.
Results
Patients
Patient characteristics are summarised in Table I. A total of 735
patients started first-line treatment; 431 patients received TKI
(sunitinib, n¼ 364; sorafenib, n¼ 67) and 304 patients received
IL2-based immunotherapy. A flowchart is shown in Figure 1. In
total 596 (81%) of the 735 patients received at least a second
cycle and were evaluable for time-dependent analyses. After
initiation but within 12-week (week 4–12) treatment 451 (82%),
88 (16%), and 153 (28%) patients had sodium LLN,
platelets5LLN, and neutrophils5LLN, respectively. A total of
224 (56%) patients had SBP140 mmHg (Table II) of which 50
patients were treated with IL2-based immunotherapy.
Median OS for all patients was 14.0 months [95% confidence
interval (CI) 12.4–15.5] and 33.4, 18.5, and 5.8 months for IMDC
favourable, intermediate, and poor risk group (p50.0001),
respectively, with a median follow-up of 50.2 months (range
1.9–81.8). Median OS was 2.5 months (95% CI 1.9–3.6) for the
139 patients who did not start a second cycle of treatment.
Univariate analyses
Univariate analyses were stratified for TKI and IL2-based
immunotherapy. The time-dependent variables obtained
within 12 weeks (week 4–12) after treatment initiation that
were significantly associated with longer OS are given in
Table II. SBP140 mmHg and DBP90 mmHg were both
significantly associated with favourable OS but these were
highly correlated (data not shown). SBP was therefore included
in the multivariate analyses as the association with OS was the
strongest.
Patients with SBP140 mmHg within 12 weeks (week 4–12)
treatment had a median OS of 18.4 (95% CI 15.3–22.3) versus
15.1 (95% CI 11.2–20.1) months for patients with SBP5
140 mmHg (p¼ 0.0206). Patients treated with IL2-based
immunotherapy and SBP140 mmHg had a median OS of
34.5 (95% CI 18.9–31.4) versus 22.7 (95% CI 24.0–NA) months
for patients with SBP5140 mmHg (p¼ 0.0274). Patients with
sodium LLN had a median OS of 19.8 (95% CI 18.0–22.4)
versus 8.3 (95% CI 6.5–13.5) months for sodium5LLN
(p50.0001).
Few patients had complete data to examine changes from
baseline to on-treatment, however, OS for 53 patients with
normalisation of sodium (LLN) from baseline5LLN was 11.5
(95% CI 10.6–20.1) compared to 6.5 months (95% CI 4.9–11.2)
for 56 patients with unchanged sodium5LLN (p¼ 0.0039).
Only 41 of 72 patients with baseline LDH41.5 times ULN
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started a second cycle of first-line treatment. Twelve patients
obtained LDH1.5 times ULN within 12 weeks (week 4–12) of
treatment resulting in almost doubling OS to 7.7 (95% CI 6.5–
NA) compared to 4.1 (95% CI 3.6–8.1) months for 20 patients
with unchanged LDH levels41.5 times ULN (p¼ 0.0481).
Multivariate analysis
There was an interaction between haemoglobin and treatment
type; demonstrating an OS benefit for patients treated with
IL2-based immunotherapy with normal haemoglobin values
during therapy while there was no effect for TKI-treated
patients. No other interactions between type of treatment and
time-dependent covariates in the multivariate analyses were
found (data not shown). Removal of haemoglobin from the
multivariate analysis enabled stratification for TKI and IL2-
based immunotherapy (Table III). Eight patients were excluded
due to missing values.
In multivariate analysis, LDH1.5 times ULN within 12
weeks (week 4–12) after treatment initiation was the strongest
predictor of OS among the five significant time-dependent
covariates with a hazard ratio (HR) of 0.45 (95% CI 0.31–0.66,
p50.0001). Sodium LLN was independently associated with
improved OS with HR of 0.63 (95% CI 0.49–0.80, p¼ 0.0002).
Similar significant HRs for OS were observed for
SBP140 mmHg, and neutrophils or platelets5LLN. These
time-dependent covariates were significantly associated with
OS independent of baseline IMDC risk group status.
Comparable results were seen if DBP was used instead of
SBP (data not shown). The C-index for baseline IMDC risk group
Table I. Baseline characteristics of patients receiving first-line TKI and IL2-based immunotherapy for metastatic renal cell carcinoma.
Variable
TKIa+ IL2-based
immunotherapy TKIa
IL2-based
immunotherapy
Total number of patients (%) 735 (100) 431 (100) 304 (100)
Emigrated (%) 4 (1) 4 (1) 0 (0)
Median age (IQR) 63 (57–69) 66 (60-73) 60 (53–64)
Male sex (%) 507 (69) 298 (69) 209 (69)
PS
0 (%) 292 (40) 120 (28) 172 (57)
1 (%) 286 (39) 176 (41) 110 (36)
2 (%) 126 (17) 116 (27) 10 (3)
3 (%) 10 (1) 10 (2) 0 (0)
NA (%) 21 (3) 9 (2) 12 (4)
IMDC
Favourable (%) 78 (11) 38 (9) 40 (13)
Intermediate (%) 364 (50) 190 (44) 174 (57)
Poor (%) 285 (39) 201 (47) 84 (28)
NA (%) 8 (1) 2 (51) 6 (2)
Known hypothyroidism (%) 24 (3) 14 (3) 10 (3)
NA (%) 2 (51) 1 (51) 1 (51)
TSH4ULN (%) 37 (6) 25 (8) 12 (5)
NA (%) 150 (20) 111 (26) 39 (13)
Known hypertension (%) 332 (45) 197 (46) 135 (44)
NA (%) 1 (51) 1 (51) 0 (0)
Systolic BP140 mmHg (%) 252 (51) 189 (51) 63 (49)
NA (%) 239 (33) 63 (15) 176 (58)
Diastolic BP90 mmHg (%) 183 (37) 130 (35) 53 (41)
NA (%) 237 (32) 62 (14) 175 (58)
Sodium5LLN (%) 182 (25) 133 (31) 49 (16)
NA (%) 4 (1) 2 (51) 2 (1)
Hemoglobin5LLN (%) 362 (49) 233 (54) 129 (43)
NA (%) 2 (51) 0 (0) 2 (1)
LDH41.5 times ULN (%) 72 (10) 55 (13) 17 (6)
NA (%) 15 (2) 11 (3) 4 (1)
Platelets4ULN (%) 207 (28) 131 (30) 76 (25)
NA (%) 3 (51) 1 (51) 2 (1)
Neutrophils4ULN (%) 222 (30) 166 (39) 56 (19)
NA (%) 7 (1) 5 (1) 2 (1)
Ca2+4ULN (%) 159 (22) 94 (22) 65 (22)
NA (%) 15 (2) 8 (2) 7 (2)
Nephrectomy performed (%) 451 (61) 239 (55) 212 (70)
Histology
Clearcell (%) 606 (82) 342 (79) 264 (87)
Non-clearcell (%) 118 (16) 83 (19) 35 (12)
NA (%) 11 (1) 6 (1) 5 (2)
Less than 1 year from diagnose (%) 548 (75) 329 (76) 219 (72)
CNS metastases present (%) 52 (7) 47 (11) 5 (2)
Liver metastases present (%) 156 (21) 105 (24) 51 (17)
Metastatic sites
1–2 (%) 365 (50) 199 (46) 166 (55)
More than 2 (%) 370 (50) 232 (54) 138 (45)
aSunitinib and sorafenib. BP, blood pressure; IL2, interleukin-2; IMDC, international mRCC Database Consortium; IQR, interquartile range;
LDH, lactate dehydrogenase; LLN, lower level of normal; NA, not applicable; PS, performance status; TKI, tyrosine kinase inhibitor; TSH,
thyroidea stimulating hormone; ULN, upper level of normal. Blood samples and blood pressures below or above levels are given as a
proportion of the available samples.
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alone in this heterogeneous cohort was 0.625 (CI 0.59–0.66)
and increased to 0.683 (CI 0.64–0.72) when baseline IMDC risk
group was combined with the five time-dependent covariates.
HRs were almost similar when multivariate analyses were
restricted to patients treated with TKI and IL2-based therapy
separately, but did not reach similar significance levels for
all variables probably due to low patient numbers in
subgroups (Supplementary Table I, available online at http://
www.informahealthcare.com).
More extreme values within the first 12-weeks of treatment
(week 4–12), such as neutropenia grade 2 (51.5 109/L) or
higher levels of sodium than LLN were associated with even
longer OS [HR 0.60 (95% CI 0.40–0.91, p¼ 0.0151 using cut-off
for neutrophils of 51.5 109/L]. Cut-offs with LLN and ULN
were chosen because they are practical and easy-to-use in the
routine clinic. It also illustrates that less extreme values are
sufficient to predict outcome.
Bootstrap validation
The multivariate analysis was internally validated with 300
random bootstrap samples (Table III). The mean HRs were
similar to the original model. The C-index from the bootstrap
analysis with combined five covariates and IMDC risk groups
was 0.685.
Biomarker index
All significant time-dependent variables were assigned 1 point
each: LDH1.5 times ULN, SBP140 mmHg, sodium LLN,
neutrophils or platelets5LLN. Any combinations of 1–5
biomarkers in a constructed biomarker index gradually reduced
the HR for death with the lowest HR seen in the index
comprising all five biomarkers (Figure 2A). LDH had higher
weight than the other covariates (black bars in Figure 2B) but
was still assigned 1 point to create a feasible and easy-to-use
tool. Of 596 patients that received at least two cycles of
treatment, 467 patients had complete data available. Patients
were assigned a biomarker profile based on numbers of
favourable features; good biomarker profile (3–5 biomarkers)
and poor biomarker profile (0–2 biomarkers) with median OS
from baseline of 23.5 (95% CI 20.8–28.0) and 9.6 (95% CI
7.2–13.8) months (p50.0001), respectively (Table IV, Figure 3A).
For the 462 patients with complete baseline and biomarker
data, OS for IMDC favourable, intermediate, and poor risk
group was 33.4 (95% CI 28.7–44.7), 19.8 (95% CI 17.4–23.8), and
9.0 (95% CI 7.4–11.4) months, respectively. OS for patients with
good versus poor biomarker profile in IMDC poor prognostic
group was 12.8 (95% CI 10.7–19.8) and 6.4 (95% CI 5.2–10.8)
months, respectively, and for patients in IMDC intermediate risk
group 25.7 (95% CI 20.9–33.6) and 12.0 (95% CI 7.9–16.5)
744 patients with confirmed diagnose
received first-line treatment for mRCC
in Denmark 2006–2010
129 patients had one or more (on
treatment) missing value(s) of the
variables in the index
596 patients received at least a second
cycle of first-line TKI or IL2-based
immunotherapy
467 patients had complete data for the
index analysis
139 patients discontinued first-line
treatment before the second cycle
735 patients were treated with first-
line TKI or IL2-based immunotherapy
9 patients received first-line treatment
with mTOR-inhibitors or dendritic cell
vaccination
5 patients had missing IMDC
classification
462 patients had complete data for the
index analysis and baseline IMDC
classification
Figure 1. Flowchart of first-line patients with mRCC treated with TKI or IL2-based
immunotherapy. IL2, interleukin-2; IMDC, International mRCC Database
Consortium; mRCC, metastatic renal cell carcinoma; mTOR, mammalian target
of rapamycin; TKI, tyrosine kinase inhibitor.
Table II. Univariate analyses of time-dependent covariates after the first cycle
but within the first 12 weeks (week 4–12) on first-line treatment of patients with
mRCC stratified by TKI and IL2-based immunotherapy.
N (%) HR 95% CI p-Value
Age 596 (100) 0.99 0.98–1.00 0.0667
Sex (male) 416 (70) 1.06 0.87–1.29 0.543
Baseline PS 0 vs. 1–3 274 (46) 0.62 0.51–0.75 50.0001
NA 17 (3)
Baseline IMDC risk group
Favourable 71 (12) 1.00
Intermediate 322 (54) 1.67 1.20–2.34 0.0027
Poor 197 (33) 3.62 2.55–5.13 50.0001
NA 6 (1)
Sodium LLN 451 (82) 0.54 0.44–0.67 50.0001
NA 44 (7)
LDH1.5 times ULN 466 (92) 0.37 0.26–0.52 50.0001
NA 92 (15)
Platelets5LLN 88 (16) 0.57 0.43–0.76 0.0001
NA 38 (6)
Neutrophils5LLN 153 (28) 0.51 0.41–0.64 50.0001
NA 42 (7)
Systolic BP140 mmHg 224 (56) 0.68 0.55–0.84 0.0004
NA 196 (33)
Diastolic BP90 mmHg 187 (47) 0.70 0.57–0.87 0.001
NA 197 (33)
TSH4ULN 70 (20) 0.81 0.60–1.10 0.1826
NA 250 (42)
Hemoglobin LLN 276 (50) 0.59 0.49–0.72 50.0001
NA 40 (7)
Ca2+ULN 441 (92) 0.66 0.46–0.93 0.0186
NA 118 (20)
BP, blood pressure; CI, confidence interval; HR, hazard ratio; IL2, interleukin-2;
IMDC, International mRCC Database Consortium; LDH, lactate dehydrogenase;
mRCC, metastatic renal cell carcinoma; N, number; NA, not applicable; PS,
performance status; TKI, tyrosine kinase inhibitor; TSH, thyroid stimulating
hormone; ULN, upper Level of normal. Blood samples and blood pressure
below or above levels are given as a proportion of the available samples.
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months (both p50.0001), respectively (Table V and Figure 3B,
C and D). A separation of OS per biomarker profile was
observed for patients in IMDC favourable risk group [38.9 (95%
CI 29.7–NA) and 28.7 (95% CI 23.4–NA) months, p¼ 0.112],
though not significant probably due to the low number of
patients (n¼ 57).
Discussion
This study is to our knowledge the first to demonstrate
that systolic hypertension, neutropenia, thrombocytopenia,
LDH1.5 times ULN, and normal sodium assessed week 4–12
after treatment initiation are independent prognostic bio-
markers associated with improved OS for patients with mRCC.
These five biomarkers were able to predict OS independent of
baseline IMDC variables and irrespectively of treatment type
and may therefore be considered as true prognostic factors.
Adjusted for baseline IMDC classification the biomarker index
provided additional significant prognostic information for
patients in IMDC intermediate and poor prognostic groups
and also provided prognostic information in IMDC favourable
group, albeit not statistically significant, probably due to the
Figure 2. Forest plot of hazard ratio’s (HR) for survival from combining biomarkers stratified for first-line treatment with tyrosine kinase inhibitors and interleukin-2
based immunotherapy. (A) HR for adding a favourable biomarker to the index adjusted for Heng risk group status. Combining all 5 favourable biomarkers resulted in
the lowest HR compared to an index consisting of only two, three or four favourable biomarkers. 1. Any biomarker. 2. Any two biomarkers. 3. Any three biomarkers. 4.
Any four biomarkers. 5. All five biomarkers. (B) HR of adding a biomarker to the index with (black bars) or without (red bars) LDH to assess the impact of LDH on the
index. 1. Any biomarker not containing LDH. 2. LDH alone. 3. Any two biomarkers not containing LDH. 4. LDH and any biomarker. 5. Any three biomarkers not
containing LDH. 6. LDH and any two biomarkers. 7. All four biomarkers not containing LDH. 8. LDH and any three biomarkers.
Table III. Multivariate analyses with bootstrap analysis of time-dependent covariates after the first cycle but within the first 12 weeks (week 4–12) on first-line
treatment of patients with mRCC stratified by TKI and IL2-based immunotherapy. N¼ 588.
Multivariate analysisa Bootstrap analysisb
HR 95% CI p-Value Mean HR 95% CI p-Value
Baseline IMDC risk group
Favourable versus poor 0.33 0.23–0.49 50.0001 0.35 0.24–0.49 50.0001
Intermediate versus poor 0.56 0.45–0.71 50.0001 0.57 0.45–0.71 50.0001
Biomarkers within 12 weeks
Sodium LLN 0.63 0.49–0.80 0.0002 0.62 0.47–0.83 0.001
LDH1.5 times ULN 0.45 0.31–0.66 50.0001 0.45 0.28–0.74 0.002
Platelets5LLN 0.66 0.48–0.91 0.0112 0.67 0.50–0.90 0.009
Neutrophils5LLN 0.75 0.57–0.98 0.0352 0.75 0.58–0.97 0.031
Systolic BP140 mmHg 0.70 0.56–0.87 0.0014 0.67 0.55–0.82 0.0001
aTime-dependent Cox proportional hazard model; b300 samples. BP, blood pressure; CI, confidence interval; HR, hazard ratio; IL2, interleukin-2; IMDC, International
mRCC Database Consortium; LDH, lactate dehydrogenase; LLN, lower level of normal; mRCC, metastatic renal cell carcinoma; TKI, tyrosine kinase inhibitor; ULN,
upper level of normal.
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low number of patients. Our findings may reflect treatment-
induced tumour biology alterations suggesting that prognostic
risk features are dynamic variables – instead of static – that
need readjustment during treatment.
Along with the detection of new biomarkers [15] inclusion of
biomarkers in established prognostic models [9–13] is needed
for improved prognostication and individualised therapies for
patients [16]. Our biomarker index is readily available, easily
obtained, and routinely measured during clinical visit.
Importantly, the biomarker index provide clinically meaningful
information by adjusting prognosis and early counselling
especially for poor and intermediate risk patients before the
first computed tomography assessment routinely obtained at a
three-month time point on top of baseline IMDC prognostic
stratification.
Low sodium at baseline has been shown to predict poor OS
for both targeted therapy and immunotherapy [6–8] but the
significance of reversal to normal sodium during treatment has
until now been unknown. The mechanism behind hypona-
traemia is not clearly understood but a relation to chronic
inflammation caused by elevated interleukin-6 has been
suggested [7,17]. Hyponatraemia could also be caused by
renal impairment though both Jeppesen et al. [6] and
Kawashima et al. [7] could not find a correlation between
hyponatraemia and estimated glomerular filtration rate,
adrenal metastases, or nephrectomy. Similarly, Marfarlane
et al. [18] found that impaired renal function did not impact
objective response or OS for patients treated with vascular
endothelial growth factor (VEGF)-targeted therapy. Other
factors, such as co-morbidity or diuretics [19,20] could
influence the development of hyponatraemia and this area
needs further research.
Elevated LDH at baseline has been shown to predict poor OS
in patients with mRCC [9,11,12,16] but the significance of LDH
below 1.5 times ULN during treatment has not been analysed
previously. In our analysis LDH had higher weight with HR of
0.45 compared to other biomarkers. However, to establish a
simple and easy-to-use tool all variables were assigned 1 point
each in the biomarker index.
Elevated TSH has been associated with improved outcome
by others [3,5,21,22] but was not associated with OS in our
study. Many of our patients did not have TSH measured prior
to each treatment cycle which resulted in a high amount of
missing values and this may have influenced our results.
Several studies have shown that adverse events, such as
hypertension, thrombocytopenia and neutropenia are bio-
markers of efficacy in patients treated with targeted therapy
[2–5]. We validated these findings and also extended the
findings to be evident during the early treatment phase
independent of type of therapy. However, it is counterintuitive
that hypertension is a biomarker of efficacy in IL2-based
Figure 3. Kaplan-Meier estimates of median overall survival (OS) per biomarker profile and combined with baseline International Metastatic renal cell carcinoma
Database Consortium (IMDC) risk group status. A good biomarker profile comprised 3–5 biomarkers within 12-weeks after treatment initiation and a poor profile
0–2 biomarkers. (A) OS for patients with a good versus poor biomarker profile. (B) OS for patients in IMDC favourable risk group with a good versus poor biomarker
profile. (C) OS for patients in IMDC intermediate risk group with a good versus poor biomarker profile. (D) OS for patients in IMDC poor risk group with a good versus
poor biomarker profile.
Table IV. Biomarker index.
On-treatment biomarkersa Observation Points
Sodium LLN 1
5LLN 0
LDH 1.5 times ULN 1
41.5 times ULN 0
Platelets 5LLN 1
LLN 0
Neutrophils 5LLN 1
LLN 0
Systolic blood pressure 140 mmHg 1
5140 mmHg 0
aMeasured after treatment start and within 12 weeks of treatment. LDH, lactate
dehydrogenase; LLN, lower level of normal; ULN, upper level of normal.
Good biomarker profile: 3–5 points.
Poor biomarker profile: 0–2 points.
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immunotherapy as it often results in hypotension when
administered. Both activation of the endothelin-1 axis [23]
and inhibition of vascular relaxation due to decreased produc-
tion of nitric oxide have been mentioned to lead to hyperten-
sion which is a group effect of VEGF inhibitors [24]. Whether
hypertension between IL-2 courses is due to the same
mechanism is unclear. BP values were obtained at every cycle
initiation after a two-week treatment break from IL2 which may
explain our findings as it could be related to baseline
hypertension [2]. Multivariate analyses looking at changes
from baseline to on-treatment values were not possible due to
a high amount of missing values.
We have recently shown that implementation of targeted
therapy did not lead to an increase in total health care costs
per patient per treatment year compared with a pre-TKI era
[25]. However, we have also previously shown that patients in
IMDC poor prognostic group had limited OS benefit from
treatment [1]. The implication of our present study is that
baseline adverse prognostic features established by Motzer
and IMDC [9,10] can be supplemented with early on-treatment
biomarkers for improved prognostication thereby better iden-
tifying patients that will benefit from treatment. Adding the
prognostic index to IMDC poor risk group adjusted prognos-
tication as patients with a good biomarker profile during early
treatment had doubled OS compared to patients with a poor
biomarker profile. Similar separation was observed for IMDC
intermediate prognostic group and a trend was seen in the
favourable group. Thus, the biomarker index identifies a
subgroup of IMDC patients that achieve clear survival benefit
from treatment. This tool may therefore aid clinicians with
supplementary prognostic information to guide treatment
counselling with the patient. However, our index needs
validation in another cohort and further testing of the relation
to outcome in patients treated with mammalian target of
rapamycin (mTOR)-inhibitors is needed as well as prospective
testing.
Limitations are the retrospective design, missing data and
low number of patients in IMDC favourable risk. Not all
available published baseline prognostic factors were included
in the multivariate model. However, we controlled for IMDC
status as no other prognostic models have shown improved
accuracy [13]. Also, the effect of the biomarkers may have been
underestimated as they were measured day 1 each cycle after a
treatment break for sunitinib and IL-2.
Conclusion
On-treatment hypertension, neutropenia, thrombocytopenia,
LDH below 1.5 times upper level of normal, and normal
sodium, obtained week 4–12 of treatment, are independent
biomarkers of favourable outcome in mRCC, independent of
treatment type.
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